| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.79 |
| 52 Week High | CN¥15.80 |
| 52 Week Low | CN¥6.30 |
| Beta | 0.41 |
| 11 Month Change | -6.22% |
| 3 Month Change | -25.30% |
| 1 Year Change | -20.58% |
| 33 Year Change | -21.68% |
| 5 Year Change | -15.13% |
| Change since IPO | -66.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603168 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.9% | 3.5% | 0.8% |
| 1Y | -20.6% | -12.5% | -21.0% |
Return vs Industry: 603168 underperformed the CN Pharmaceuticals industry which returned -12.5% over the past year.
Return vs Market: 603168 matched the CN Market which returned -21% over the past year.
Price Volatility
| 603168 volatility | |
|---|---|
| 603168 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 603168's share price has been volatile over the past 3 months.
Volatility Over Time: 603168's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 1,385 | n/a | www.zjspas.com |
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes.
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603168 fundamental statistics | |
|---|---|
| Market cap | CN¥2.57b |
| Earnings (TTM) | CN¥7.18m |
| Revenue (TTM) | CN¥620.60m |
358.6x
P/E Ratio4.1x
P/S RatioIs 603168 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603168 income statement (TTM) | |
|---|---|
| Revenue | CN¥620.60m |
| Cost of Revenue | CN¥282.21m |
| Gross Profit | CN¥338.40m |
| Other Expenses | CN¥331.22m |
| Earnings | CN¥7.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 31, 2024
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 54.53% |
| Net Profit Margin | 1.16% |
| Debt/Equity Ratio | 9.9% |
How did 603168 perform over the long term?
See historical performance and comparison